Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD Study of CD388 in Healthy Japanese Adults
NCT05619536Phase 1Completed
- Sponsor
- Cidara Therapeutics
- Start
- Oct 2022
- Primary completion
- Jul 2023
- Modality
- Small Molecules, Fc Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of retezrelvir in influenza (3 cohorts), sponsored by Cidara Therapeutics. Primary endpoints: Number of Treatment-Emergent Adverse Events and Severity of Treatment-Emergent Adverse Events. Started Oct 2022; status: completed.
02
Drugs
retezrelvir
03
Conditions
influenza
Beyond the preview
Go deeper on NCT05619536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05619536.